SYDNEY: Firebrick Pharma Limited (ASX: FRE) announced the formation of a Scientific Advisory Board (SAB) to guide the Company’s research and development initiatives, including current new product development plans.
The members of the SAB have all conducted extensive medical research throughout their respective careers and bring a wealth of international medical and scientific experience to Firebrick Pharma.
Members of the initial SAB cohort are:
• Prof Richard Strugnell: Academic microbiologist and Fellow of the Australian Society of Microbiology.
• Prof Ronald Turner: A Professor at the University of Virginia School of Medicine and a prominent researcher in viral respiratory infections.
• Prof Andrew Wilks: A Fellow to the Australian Academy of Health and Medical Sciences and founder and co-founder of multiple biotech companies.
• Dr Bobby Singh: An accomplished pharmaceutical executive and lead inventor or co-inventor of more than 25 patents.
The SAB will work alongside Firebrick Board members: Dr Peter Molloy, Dr Stephen Goodall, Prof Phyllis Gardner and Dr Richard Treagus, who will participate in SAB meetings.
The SAB will be chaired by Firebrick Chief Scientific Officer, Dr Simon Tucker. Dr Tucker is a virologist with decades of pharmaceutical R&D management experience. He has previously led teams at GD Searle (US) and Biota Pharmaceuticals, focused on the discovery and development of antiviral drugs.
“We are very privileged to be able to work with such an esteemed group of international scientific advisors,” said Dr Tucker.
“The SAB will play a key role in advising Firebrick on our R&D direction as well as providing insights on new developments and potential opportunities. Their experience provides a tremendous sounding board and expert guidance for the company.”